Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer have?
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer has 447 citations in the OpenAlex counts ScholarIQ stores.
When was Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer published?
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer has 2023 year in the ScholarIQ index.
What is the open-access status of Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer?
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer has green oa status in the ScholarIQ index.
What is the DOI of Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer?
The DOI for Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer is on the source record.
What is the PMID of Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer?
The PMID for Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer is on the source record.
What is the OpenAlex record for Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer?
The OpenAlex for Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer is on the source record.